AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Amylyx Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$27.33+0.99 (+3.76%)

Close on Oct 19, 2026

Market cap: $3.04B
P/E (TTM): –
Dividend yield: –

Amylyx Pharmaceuticals, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0	87	381	22	0.29
Cost of Revenue	0	5.95	25	2.99	–
Gross Profit	0	81	355	19	–
Research & Development	90	104	128	93	44
Selling, General & Admin	63	114	188	127	39
Advertising Expenses	–	2.70	9.50	4.40	–
Total Costs & Expenses	153	402	342	224	83
Operating Income	-153	-315	39	-201	-83
Interest & Investment Income	9.30	14	16	4.29	0.04
Other Non-Operating Income	8.60	13	15	3.74	-5.24
Merger & Restructuring Charges	0	23	–	–	–
Asset Impairment Charges	–	0.96	0	0	0
Pretax Income	-145	-302	54	-198	-88
Income Tax Expense	0.05	-0.39	5.03	0.77	–
Net Income incl. Noncontrolling Interests	-145	-302	49	-198	-88
Net Income	-145	-302	49	-198	-88
EPS (Basic)(per share)	-1.53	-4.43	0.73	-3.39	-13.35
EPS (Diluted)(per share)	-1.53	-4.43	0.70	-3.39	-13.35
Shares Outstanding (Basic, Weighted)(shares)	95	68	67	58	6.59
Shares Outstanding (Diluted, Weighted)(shares)	95	68	70	58	6.59

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -61.6%

Financial strength

Current ratio: 12.12
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 233.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 12.71
Dividend yield: –